Unicharm Corp 2Q Operating Income Beats Estimates by 19% – 7 Buys, 5 Holds, 1 Sell

• Unicharm reported a 2Q operating income of 30.32 billion yen, a 19% increase year on year and higher than the estimated 28.69 billion yen.
• Net income was 18.15 billion yen, a 22% increase from the same period last year and higher than the estimated 17.5 billion yen.
• Net sales were 233.10 billion yen, a 7.3% increase from the same period last year and equal to the estimated 232.89 billion yen.
• Unicharm still expects operating income to reach 141.00 billion yen, higher than the estimated 137.04 billion yen.
• The company also expects net income to total 80.90 billion yen, slightly lower than the estimated 83.08 billion yen.
• Unicharm has forecast net sales of 963.50 billion yen, slightly higher than the estimated 945.43 billion yen.
• The company also expects to pay out a dividend of 40.00 yen, slightly lower than the estimated 40.22 yen.
• Among analysts, 7 have rated Unicharm as a ‘buy’, 5 as a ‘hold’, and 1 as a ‘sell’.

A look at Unicharm Corp Smart Scores

Unicharm Corp is a promising company. Its Smartkarma Smart Scores indicate that the company has a good outlook for the long-term. The company has strong resilience, with a score of 4, and good growth potential, with a score of 3. Unicharm Corp is a manufacturer of sanitary napkins and baby products, infant & adult diapers, household cleaning wipes, and feminine hygienic products. Additionally, the company produces pet food and pet toiletries, as well as operates educational and finance businesses.

The company’s value score of 2 and momentum score of 2 indicate that it may not be the best choice for investors looking for short-term gains. However, for those looking to invest in the long-term, Unicharm Corp looks like a solid bet. With its strong resilience and good growth potential, the company is well-positioned for the long-term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma